Twist Bioscience Corporation TWST, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it intends to offer and sell in an underwritten public offering up to $250 million of shares of its common stock and certain selling stockholders intend to offer 75,000 shares in the offering. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to $37.5 million of shares of its common stock offered by it in the public offering.